Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
5
×
gene therapy
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
5
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
biogen
glaxosmithkline
medical devices
spinal muscular atrophy
abbvie
akcea therapeutics
amgen
anemia
astrazeneca
What
bio
roundup
cancer
days
democrats
ipo
abbvie’s
ahead
allogene
alzheimer’s
america
august
biofourmis
biogen
biotech
bucks
busy
celebrate
chance
congress
continues
convoluted
corner
crispr
day
decisions
devices
diversity
divided
dreams
drugs
elections
fallout
fda
forward
head
headaches
healthcare
holding
holiday
Language
unset
Current search:
novartis
×
" gene therapy "
×
fda
×
" seattle blog main "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More